Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
59
RLAY Quote, Financials, Valuation and Earnings
Last price:
$8.01
Seasonality move
:
-10.52%
Day range:
$7.53 - $7.92
52-week range:
$1.78 - $8.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
159.35x
P/B ratio:
2.23x
Volume:
1.3M
Avg. volume:
2.2M
1-year change:
78.36%
Market cap:
$1.4B
Revenue:
$10M
EPS (TTM):
-$1.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RLAY
Relay Therapeutics, Inc.
|
$147.5K | -$0.42 | -99.89% | -14.66% | $13.90 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 97.59% | -58.59% | $492.17 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$157.3M | -$0.16 | 9168.67% | -72.35% | $57.67 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 64.56% | -3.9% | $220.41 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.66% | -35.2% | $8.25 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$247.7M | -$1.99 | 201.43% | -81.62% | $563.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RLAY
Relay Therapeutics, Inc.
|
$7.83 | $13.90 | $1.4B | -- | $0.00 | 0% | 159.35x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$473.29 | $492.17 | $62.5B | 1,967.94x | $0.00 | 0% | 19.42x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$65.08 | $57.67 | $8.8B | -- | $0.00 | 0% | 10.48x |
|
INSM
Insmed, Inc.
|
$206.78 | $220.41 | $44.1B | -- | $0.00 | 0% | 88.00x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.21 | $8.25 | $877.3M | -- | $0.00 | 0% | 2.93x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$579.89 | $563.80 | $13.2B | -- | $0.00 | 0% | 17.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RLAY
Relay Therapeutics, Inc.
|
5.2% | 3.076 | 3.7% | 18.29x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
61.15% | 4.654 | 15.55% | 4.74x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RLAY
Relay Therapeutics, Inc.
|
-$748K | -$80.4M | -38.91% | -41.21% | -11351.11% | -$62.1M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$250.1M | $44.1M | 2.57% | 7.7% | 17.2% | $13M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
Relay Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RLAY or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 20.1%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About RLAY or ALNY?
Relay Therapeutics, Inc. has a consensus price target of $13.90, signalling upside risk potential of 77.52%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 3.99%. Given that Relay Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLAYRelay Therapeutics, Inc.8 2 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is RLAY or ALNY More Risky?
Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock RLAY or ALNY?
Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLAY or ALNY?
Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,967.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 159.35x versus 19.42x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLAYRelay Therapeutics, Inc.159.35x -- -- -$74.1M ALNYAlnylam Pharmaceuticals, Inc.19.42x 1,967.94x $1.2B $251.1M
-
Which has Higher Returns RLAY or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 6.29%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.
Company Gross Margin Earnings Per Share Invested Capital RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M ARWRArrowhead Pharmaceuticals, Inc.97.51% -$0.18 $1.2B -
What do Analysts Say About RLAY or ARWR?
Relay Therapeutics, Inc. has a consensus price target of $13.90, signalling upside risk potential of 77.52%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $57.67 which suggests that it could fall by -11.38%. Given that Relay Therapeutics, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLAYRelay Therapeutics, Inc.8 2 0 ARWRArrowhead Pharmaceuticals, Inc.7 4 0 -
Is RLAY or ARWR More Risky?
Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.
-
Which is a Better Dividend Stock RLAY or ARWR?
Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLAY or ARWR?
Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 159.35x versus 10.48x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLAYRelay Therapeutics, Inc.159.35x -- -- -$74.1M ARWRArrowhead Pharmaceuticals, Inc.10.48x -- $256.5M $16.1M
-
Which has Higher Returns RLAY or INSM?
Insmed, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of -259.95%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About RLAY or INSM?
Relay Therapeutics, Inc. has a consensus price target of $13.90, signalling upside risk potential of 77.52%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that Relay Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLAYRelay Therapeutics, Inc.8 2 0 INSMInsmed, Inc.16 1 0 -
Is RLAY or INSM More Risky?
Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock RLAY or INSM?
Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLAY or INSM?
Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Relay Therapeutics, Inc.'s net income of -$74.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 159.35x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLAYRelay Therapeutics, Inc.159.35x -- -- -$74.1M INSMInsmed, Inc.88.00x -- $142.3M -$370M
-
Which has Higher Returns RLAY or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of -135.28%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About RLAY or IOVA?
Relay Therapeutics, Inc. has a consensus price target of $13.90, signalling upside risk potential of 77.52%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 273.3%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Relay Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Relay Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLAYRelay Therapeutics, Inc.8 2 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is RLAY or IOVA More Risky?
Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock RLAY or IOVA?
Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLAY or IOVA?
Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Relay Therapeutics, Inc.'s net income of -$74.1M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 159.35x versus 2.93x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLAYRelay Therapeutics, Inc.159.35x -- -- -$74.1M IOVAIovance Biotherapeutics, Inc.2.93x -- $67.5M -$91.3M
-
Which has Higher Returns RLAY or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of -39.75%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About RLAY or MDGL?
Relay Therapeutics, Inc. has a consensus price target of $13.90, signalling upside risk potential of 77.52%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $563.80 which suggests that it could fall by -2.78%. Given that Relay Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLAYRelay Therapeutics, Inc.8 2 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is RLAY or MDGL More Risky?
Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock RLAY or MDGL?
Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLAY or MDGL?
Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Relay Therapeutics, Inc.'s net income of -$74.1M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 159.35x versus 17.36x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLAYRelay Therapeutics, Inc.159.35x -- -- -$74.1M MDGLMadrigal Pharmaceuticals, Inc.17.36x -- $287.3M -$114.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
